MX2022012578A - N-cianopirrolidinas con actividad como inhibidores de usp30. - Google Patents
N-cianopirrolidinas con actividad como inhibidores de usp30.Info
- Publication number
- MX2022012578A MX2022012578A MX2022012578A MX2022012578A MX2022012578A MX 2022012578 A MX2022012578 A MX 2022012578A MX 2022012578 A MX2022012578 A MX 2022012578A MX 2022012578 A MX2022012578 A MX 2022012578A MX 2022012578 A MX2022012578 A MX 2022012578A
- Authority
- MX
- Mexico
- Prior art keywords
- cyanopyrrolidines
- activity
- inhibitors
- usp30
- usp30 inhibitors
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical class N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 title abstract 2
- 101150099494 Usp30 gene Proteins 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 101000748132 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 30 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000004065 mitochondrial dysfunction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005250.2A GB202005250D0 (en) | 2020-04-08 | 2020-04-08 | Novel compounds |
| GBGB2016607.0A GB202016607D0 (en) | 2020-10-20 | 2020-10-20 | Novel Compounds |
| PCT/EP2021/059032 WO2021204856A1 (en) | 2020-04-08 | 2021-04-07 | N-cyanopyrrolidines with activity as usp30 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012578A true MX2022012578A (es) | 2022-11-07 |
Family
ID=75441909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012578A MX2022012578A (es) | 2020-04-08 | 2021-04-07 | N-cianopirrolidinas con actividad como inhibidores de usp30. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230119013A1 (enExample) |
| EP (1) | EP4132925A1 (enExample) |
| JP (1) | JP2023520727A (enExample) |
| KR (1) | KR20230006487A (enExample) |
| CN (1) | CN115461340A (enExample) |
| AU (1) | AU2021253617A1 (enExample) |
| BR (1) | BR112022020058A2 (enExample) |
| CA (1) | CA3171349A1 (enExample) |
| CO (1) | CO2022014134A2 (enExample) |
| IL (1) | IL296998A (enExample) |
| MX (1) | MX2022012578A (enExample) |
| WO (1) | WO2021204856A1 (enExample) |
| ZA (1) | ZA202212137B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021245186A1 (en) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| RS67140B1 (sr) | 2020-06-08 | 2025-09-30 | Mission Therapeutics Ltd | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| CN117887844B (zh) * | 2023-12-28 | 2024-08-23 | 中山大学附属第一医院 | Usp20在肝癌放疗增敏中的应用 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
| GB202500610D0 (en) | 2025-01-16 | 2025-03-05 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| JP2003530384A (ja) | 2000-04-06 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | カテプシンシステインプロテアーゼ阻害薬 |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2007119214A2 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| US20090264431A1 (en) | 2007-08-20 | 2009-10-22 | Palovich Michael R | Novel cathepsin c inhibitors and their use |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| UY31770A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
| UY31771A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| JP6612751B2 (ja) | 2013-07-31 | 2019-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| US20170095457A1 (en) | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| LT3277677T (lt) * | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| MA43753A (fr) * | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) * | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| AU2018346597B2 (en) * | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP3837262B1 (en) * | 2018-08-14 | 2026-06-17 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| EP4218934B1 (en) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
-
2021
- 2021-04-07 MX MX2022012578A patent/MX2022012578A/es unknown
- 2021-04-07 KR KR1020227038744A patent/KR20230006487A/ko not_active Withdrawn
- 2021-04-07 WO PCT/EP2021/059032 patent/WO2021204856A1/en not_active Ceased
- 2021-04-07 US US17/914,414 patent/US20230119013A1/en not_active Abandoned
- 2021-04-07 CA CA3171349A patent/CA3171349A1/en active Pending
- 2021-04-07 JP JP2022561565A patent/JP2023520727A/ja active Pending
- 2021-04-07 EP EP21717825.0A patent/EP4132925A1/en not_active Withdrawn
- 2021-04-07 CN CN202180023434.1A patent/CN115461340A/zh active Pending
- 2021-04-07 BR BR112022020058A patent/BR112022020058A2/pt not_active IP Right Cessation
- 2021-04-07 IL IL296998A patent/IL296998A/en unknown
- 2021-04-07 AU AU2021253617A patent/AU2021253617A1/en not_active Abandoned
-
2022
- 2022-09-30 CO CONC2022/0014134A patent/CO2022014134A2/es unknown
- 2022-11-07 ZA ZA2022/12137A patent/ZA202212137B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3171349A1 (en) | 2021-10-14 |
| CO2022014134A2 (es) | 2022-10-31 |
| EP4132925A1 (en) | 2023-02-15 |
| CN115461340A (zh) | 2022-12-09 |
| WO2021204856A1 (en) | 2021-10-14 |
| IL296998A (en) | 2022-12-01 |
| KR20230006487A (ko) | 2023-01-10 |
| AU2021253617A1 (en) | 2022-12-01 |
| JP2023520727A (ja) | 2023-05-18 |
| US20230119013A1 (en) | 2023-04-20 |
| ZA202212137B (en) | 2024-07-31 |
| BR112022020058A2 (pt) | 2022-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202203775B (en) | Substituted cyanopyrrolidines with activity as usp30 inhibitors | |
| ZA202212137B (en) | N-cyanopyrrolidines with activity as usp30 inhibitors | |
| ZA202213866B (en) | N-cyanopyrrolidines with activity as usp30 inhibitors | |
| CO2022017233A2 (es) | 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis | |
| MX2023000998A (es) | Composiciones genomodificadas dirigidas a los musculos. | |
| MX2022014429A (es) | N-cianopirrolidinas con actividad como inhibidores de usp30. | |
| PH12023550161A1 (en) | Pharmaceutical composition and use thereof | |
| MX2016006489A (es) | Alfa-amilasas variantes que tienen susceptibilidad reducida a la escision por proteasas y metodos de uso. | |
| MY167691A (en) | A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid | |
| ZA202308327B (en) | Methyl-substituted pyridine and pyridazine compounds, derivatives thereof, and methods of their use | |
| MA40791A (fr) | Ciblage lysosomal d'enzymes et utilisations associées | |
| WO2023081830A3 (en) | Compositions and treatments with nirogacestat | |
| MX2022005450A (es) | Composiciones que contienen cannabidiol (cbd) de accion periferica y usos de las mismas para mejorar la funcion sexual femenina o tratar trastornos sexuales femeninos. | |
| EP4711007A3 (en) | 5'-o-phenylacetyluridine and therapeutic use | |
| MX2023000164A (es) | Métodos y composiciones para tratar la hemofilia. | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| PH12022553030A1 (en) | Pharmaceutical formulations of abiraterone acetate and niraparib | |
| MX2023002416A (es) | Compuestos, composiciones y metodos para la inhibicion de la desmetilasa de histona lisina. | |
| ZA202403575B (en) | Method for promoting cell endocytosis of vegetable albumin, and application thereof | |
| ZA202210918B (en) | Novel il10 agonists and methods of use thereof | |
| WO2020222241A8 (en) | Compositions comprising the propeptide of lysyl oxidase and uses thereof | |
| MX2024004011A (es) | Composiciones moduladoras de precalicreína y métodos de uso de estas. | |
| WO2023056365A3 (en) | Irhom2 inhibitors and uses thereof | |
| PL414890A1 (pl) | Środek aktywujący | |
| PH12016500471A1 (en) | Method to treat onychomycosis by hydroxypropyl chitosan |